Martin Bush (A), Katerina Kontogeorgiou & Maria Pouloudi (GR), Etienne Maffli (CH), Ton Ouwehan & Wil Kuijpers (NL), Bela Studnickova (CZ) Coordination: Linda Montanari, Paul Griffiths, Colin Taylor (EMCDDA) TDI 2006 Annual expert meeting, 25-26 September 2006, Lisbon Gender differences among treatment patients of some European countries (Austria, Czech Republic, Greece, Switzerland, The Netherlands)
24
Embed
Gender differences among treatment patients of some European countries
Gender differences among treatment patients of some European countries (Austria, Czech Republic, Greece, Switzerland, The Netherlands). Martin Bush (A), Katerina Kontogeorgiou & Maria Pouloudi (GR), Etienne Maffli (CH), Ton Ouwehan & Wil Kuijpers (NL), Bela Studnickova (CZ) - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Martin Bush (A), Katerina Kontogeorgiou & Maria Pouloudi (GR), Etienne Maffli (CH), Ton Ouwehan & Wil Kuijpers (NL),
Bela Studnickova (CZ)
Coordination: Linda Montanari, Paul Griffiths, Colin Taylor (EMCDDA)
TDI 2006 Annual expert meeting, 25-26 September 2006, Lisbon
Gender differences among treatment patients of some
European countries(Austria, Czech Republic, Greece, Switzerland, The Netherlands)
General aims
• assessing gender differences among treatment patients with drug-related problems in 5 European countries by means of TDI data
• comparing the resulting figures with external indicators (general population, drug-related death, police notifications, treatment organisation)
• drawing conclusions about possible differences between male and female clients, particularly with regard to the access to treatment, taking possible country-related disparities into account
Topics investigated with treatment data
overall gender distribution in treatment population (new clients, all clients), and by primary drug
gender distribution by age groups (new clients)
source of referral by primary drug and gender (new clients)
age at first use by primary drug and gender (new clients)
time lag between first use and first treatment by primary drug and gender (new clients)
External indicators
gender distribution in the total population (2003)
drug-related death (DRD) by age and gender (2003)
notifications by the police by age, gender and substance (2003)
share of treatment units participating in the monitoring system offering gender specific intervention (2003)
Proportion of males and females in the general population (2003)
0 50 100
The Netherlands
Switzerland
Greece
Czech Republic
Austria
females males
%
Total treatment demandby gender and by country (2003)
16.6%
17.7%
29.3%
26.3%
31.1%
0 25 50 75 100
The Netherlands
Switzerland
Greece
Czech Republic
Austria
females males
%
First treatment demandby gender and by country (2003)
16.7%
21.4%
24.8%
25.6%
32.8%
0 25 50 75 100
The Netherlands
Switzerland
Greece
Czech Republic
Austria
females males Barres 3 Barres 4 Barres 5 Barres 6
%
Netherlands Austria Switzerland GreeceCzech
Republic
Opiates 3,7 3,0 3,5 5,1 2,2
Cocaïne 4,2 n.a. 2,4 4,0 0,9
Stimulants 2,7 n.a. 0,3 2,7 1,7
Cannabis 4,2 n.a. 4,2 5,3 2,8
Other Substances 1,1 n.a 1,0 2,8 4,1
Total 3,7 3,0 2,9 5,0 2,0
Male to female ratio by primary drug and by country (first treatment demand, 2003)
Drug related deaths by gender and by country according to age groups (2003)
1) Federal Ministry for Health and Women – calculations by Austrian Health Institute; 2) EMCDDA Statistical Table 5; 3) Swiss Federal Statistical Office
Drug-related police notifications by substance and gender in Austria, Switzerland and The
Primary drug at first treatment by gender and by country (2003)
15.9
15.8
28.6
33.5
83.3
84.7
14.7
16.3
36.9
42
26
20.7
0.6
0.3
8.9
6.5
7.8
0.9
62.6
52.1
28.9
32.9
29.9
42.3
11
11.8
19
26
9.4
2.8
7.7
2.6
3.2
1.7
3.1
5.3
1.6
1.3
0.9
0.5
0% 20% 40% 60% 80% 100%
female
male
female
male
female
male
female
male
Th
eN
eth
erl
an
ds
Sw
itze
rla
nd
G
ree
ce
Cze
chR
ep
ub
lic
Opiates Cocaine Stimulants Cannabis Others
Most important source of referral among first treatment patients by gender and country - primary drug: opiates
(2003)
3.6
5.2
0.5
4.6
2.1
7.2
10.8
66
4.1
5.7
0.5
1.6
5.4
9.5
70.7
2.5
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=194) male (N=441)
CZ GR
4.5
0.8
1.9
1.9
2.3
7.9
56.2
24.5
6.9
1.1
1.4
2
7.1
57.5
22.2
1.7
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=265) male (N=1324)
0
20
10
5
15.0
0.0
20
30
4.1
11
5.5
8.2
6.8
13.7
35.6
15.1
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=20) male (N=73)
CH
9.6
9.6
0.9
4.4
5.3
16.7
3.5
50
7
22
1.5
3.5
10.5
2.4
45.8
7.4
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=114) male (N=459)
NL
Most important source of referral among first treatment patients by gender and country – primary drug: stimulants
(2003)
10.1
2.6
3.7
2.3
2.4
2.8
22.2
54
8.4
4.1
1.6
0.9
2.5
13.2
67
2.3
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=794) male (N=1374)
Czech Republic
9.2
2.6
1.3
13.2
21.1
5.3
3.9
43.4
11
22.4
0.9
9.1
4.1
4.6
34.7
13.2
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=76) male (N=219)
The Netherlands
Most important source of referral among first treatment patients by gender and country – primary drug: cannabis
(2003)
CZ GR
10.6
1.6
3.3
1.6
4.1
0.8
37.6
40.4
10.6
4.1
3.1
2.2
2.2
34.7
37.8
5.4
0 10 20 30 40 50
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=245) male (N=688)
2.9
2.9
8.6
0
8.6
5.7
65.7
5.7
4.3
5.9
2.7
2.7
5.9
63.6
14.4
0.5
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=35) male (N=187)
23.8
0
4.8
14.3
0.0
4.8
28.6
23.8
15.4
15.4
9.9
9.9
5.5
33
9.9
1.1
0 10 20 30 40 50
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=21) male (N=91)
9.3
3.2
1.6
19
13.7
13.3
4.8
35.1
8.2
14
2
10.9
8.2
5.3
37.9
13.6
0 20 40 60 80
other
justice
social services
hospital /medical
GP
other centre
family / friends
self-referred
female (N=248) male (N=1046)
NLCH
%
% %
%
19.8
21.3 21.2
26.2
1919.9
20.7 20.6
12
14
16
18
20
22
24
26
28
CZ GR CH NL
Male Female
18.3
16
17.1 17
12
14
16
18
20
22
24
26
28
CZ GR CH NL
Male Female
15.516.2 16.3
14.815.5 15.6
12
14
16
18
20
22
24
26
28
CZ GR CH NL
Male Female
Opiates Stimulants Cannabis
Age Age Age
Mean age at first use among male and female clients (first treatment) by primary drug
and country (2003)
Time lag between first use and first treatment among male and female clients by primary
drug and country (2003)
4.4
7.4 7.7
11.4
4
5.9 5.7
14.7
0
2
4
6
8
10
12
14
16
CZ GR CH NL
Male Female
6.3
10.1
4.3
3.2
10.4
3.2
0
2
4
6
8
10
12
14
16
CZ GR CH NL
Male Female
3.6
8.1
2.5
6.6
0
2
4
6
8
10
12
14
16
CZ GR CH NL
Male Female
Opiates CannabisStimulants
years yearsyears
Preliminary conclusions I
Females are a minority of the treated population in the five countries, ranging from 16.7% in Greece to 32.8% in the Czech Republic.
The share of female clients is generally higher in low age groups than in older groups (except in The Netherlands), but still smaller than the share of male clients
The gender distribution seems also to vary according the primary drug: the highest share of female clients is observed among stimulant abusers whereas the lowest proportions are generally seen among opiate and cannabis abusers
No cross-cultural and overall gender-specific differences regarding the source of referrals of the clients monitored seem to prevail. The differences observed between the countries seem to be much more prominent than the differences related to the gender
Preliminary conclusions II
Female clients report generally an average younger age at first use than male clients do (except in The Netherlands among stimulant abusers). They are also generally younger at their first treatment demand than male clients
Compared with other sources of data (drug-related notifications and drug-related deaths), the proportion of females is often higher in the treatment data, suggesting that accessibility to treatment facilities is at least equal or even better for females than for males
Also the the observation that female clients generally show a shorter time lag between first use and first treatment than male clients (except for the Netherlands among opiate abusers) corroborates the assumption that access to treatment is not impaired for female substance abusers, compared with males